Previous close | 0.8639 |
Open | 0.8500 |
Bid | 0.8600 x 2900 |
Ask | 0.8752 x 800 |
Day's range | 0.8300 - 0.9040 |
52-week range | 0.6000 - 1.4500 |
Volume | |
Avg. volume | 151,051 |
Market cap | 110.684M |
Beta (5Y monthly) | 0.22 |
PE ratio (TTM) | 85.00 |
EPS (TTM) | 0.0100 |
Earnings date | 06 May 2024 - 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.93 |
BELGRADE, Mont., April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™. “The launches of SimpliGraft and SimpliMax highlights the strength of our newly revitalized Research and Development team,” said Sean Browne, President and CEO of Xtant Medical. “We
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call Transcript April 1, 2024 Xtant Medical Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.025. Xtant Medical Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
Q4 2023 Xtant Medical Holdings Inc Earnings Call